{
    "root": "21fb1417-f256-425d-bcdd-0bad63e33e4d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "sumatriptan",
    "value": "20250423",
    "ingredients": [
        {
            "name": "SUMATRIPTAN SUCCINATE",
            "code": "J8BDZ68989"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "sumatriptan 25 mg , 50 mg 100 mg tablets indicated acute treatment migraine without aura adults . limitations : clear diagnosis migraine headache established . patient response first migraine attack treated sumatriptan tablets , reconsider diagnosis migraine sumatriptan administered treat subsequent attacks . sumatriptan tablets indicated prevention migraine attacks . safety effectiveness sumatriptan tablets established cluster headache .",
    "contraindications": "single dose 25-mg , 50-mg , 100-mg tablet . ( 2.1 ) second dose considered response first dose observed . separate doses least 2 hours . ( 2.1 ) maximum dose 24-hour period : 200 mg. ( 2.1 ) maximum single dose exceed 50 mg patients mild moderate hepatic impairment . ( 2.2 )",
    "warningsAndPrecautions": "sumatriptan 25 mg , 50 mg 100 mg tablets supplied film-coated , round shaped , tablets following strengths . sumatriptan tablets usp , 25 mg : round , white colored film-coated tablets debossed “ v ” one side “ 22 ” side . supplied : bottle pack 36 tablets ndc 64980-660-36 blister packs 9 tablets ( 1 blister 9 tablets ) ndc 64980-660-91 blister packs 27 tablets ( 3 blisters 9 tablets ) ndc 64980-660-27 sumatriptan tablets usp , 50 mg : round , white colored film-coated tablets debossed “ v ” one side “ 23 ” side . supplied : bottle pack 36 tablets ndc 64980-661-36 blister packs 9 tablets ( 1 blister 9 tablets ) ndc 64980-661-91 blister packs 27 tablets ( 3 blisters 9 tablets ) ndc 64980-661-27 sumatriptan tablets usp , 100 mg : round , pink colored film-coated tablets debossed “ v ” one side “ 24 ” ' side . supplied : bottle pack 36 tablets ndc 64980-662-36 blister packs 9 tablets ( 1 blister 9 tablets ) ndc 64980-662-91 blister packs 27 tablets ( 3 blisters 9 tablets ) ndc 64980-662-27 store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "sumatriptan tablets contraindicated patients : ischemic coronary artery disease ( cad ) ( angina pectoris , history myocardial infarction , documented silent ischemia ) coronary artery vasospasm , including prinzmetal ’ angina [ ( 5.1 ) ] wolff-parkinson-white syndrome arrhythmias associated cardiac accessory conduction pathway disorders [ ( 5.2 ) ] history stroke transient ischemic attack ( tia ) history hemiplegic basilar migraine patients higher risk stroke [ ( 5.4 ) ] peripheral vascular disease [ ( 5.5 ) ] ischemic bowel disease [ ( 5.5 ) ] uncontrolled hypertension [ ( 5.8 ) ] recent ( i.e . , within 24 hours ) ergotamine-containing medication , ergot-type medication ( dihydroergotamine methysergide ) , another 5-hydroxytryptamine1 ( 5-ht1 ) agonist [ ( 7.1 , 7.3 ) ] concurrent monoamine oxidase ( mao ) -a inhibitor recent ( within 2 weeks ) mao-a inhibitor [ ( 7.2 ) , pharmacology ( 12.3 ) ] hypersensitivity sumatriptan tablets ( angioedema anaphylaxis seen ) [ ( 5.9 ) ] severe hepatic impairment [ ( 8.6 ) , pharmacology ( 12.3 ) ]",
    "indications_original": "Sumatriptan 25 mg, 50 mg and 100 mg tablets are indicated for the acute treatment of migraine with or without aura in adults.\n                  \n                     Limitations of Use:\n                  \n                  \n                     Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan tablets, reconsider the diagnosis of migraine before sumatriptan is administered to treat any subsequent attacks.\n                     Sumatriptan tablets are not indicated for the prevention of migraine attacks.\n                     Safety and effectiveness of sumatriptan tablets have not been established for cluster headache.",
    "contraindications_original": "Single dose of 25-mg, 50-mg, or 100-mg tablet. ( 2.1 ) A second dose should only be considered if some response to the first dose was observed. Separate doses by at least 2 hours. ( 2.1 ) Maximum dose in a 24-hour period: 200 mg. ( 2.1 ) Maximum single dose should not exceed 50 mg in patients with mild to moderate hepatic impairment. ( 2.2 )",
    "warningsAndPrecautions_original": "Sumatriptan 25 mg, 50 mg and 100 mg tablets are supplied as film-coated, round shaped, tablets in the following strengths.\n                  Sumatriptan Tablets USP, 25 mg: Round, White colored film-coated tablets debossed with “V” on one side and “22”on the other side. They supplied as:\n                  Bottle pack of 36 tablets                                                 NDC 64980-660-36\n                  Blister packs of 9 tablets (1 blister of 9 tablets)             NDC 64980-660-91\n                  Blister packs of 27 tablets (3 blisters of 9 tablets)         NDC 64980-660-27\n                  Sumatriptan Tablets USP, 50 mg: Round, White colored film-coated tablets debossed with “V” on one side and “23” on the other side. They supplied as:\n                  Bottle pack of 36 tablets                                                 NDC 64980-661-36\n                  Blister packs of 9 tablets (1 blister of 9 tablets)             NDC 64980-661-91\n                  Blister packs of 27 tablets (3 blisters of 9 tablets)         NDC 64980-661-27\n                  Sumatriptan Tablets USP, 100 mg: Round, Pink colored film-coated tablets debossed with “V”on one side and “24”' on the other side. They supplied as:\n                  Bottle pack of 36 tablets                                                 NDC 64980-662-36\n                  Blister packs of 9 tablets (1 blister of 9 tablets)             NDC 64980-662-91\n                  Blister packs of 27 tablets (3 blisters of 9 tablets)         NDC 64980-662-27\n                  Store between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature].",
    "adverseReactions_original": "Sumatriptan tablets are contraindicated in patients with:\n                  \n                     Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1)]\n                     \n                     Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)]\n                     \n                     History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)]\n                     \n                     Peripheral vascular disease [see  Warnings and Precautions (5.5)]\n                     \n                     Ischemic bowel disease [see  Warnings and Precautions (5.5)]\n                     \n                     Uncontrolled hypertension [see Warnings and Precautions (5.8)]\n                     \n                     Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7.1, \n                           7.3)]\n                     \n                     Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2), Clinical Pharmacology (12.3)]\n                     \n                     Hypersensitivity to sumatriptan tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)]\n                     \n                     Severe hepatic impairment [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]"
}